50
Participants
Start Date
December 29, 2020
Primary Completion Date
January 10, 2022
Study Completion Date
February 18, 2022
GEM103
GEM103 500 mcg/50 mcL intravitreal injection
Aflibercept
"Aflibercept 2 mg/50 mcL (SOC) intravitreal injection~Sham intravitreal injection"
Sham
Sham intravitreal injection
Gemini Clinical Trial Site 4, Hagerstown
Gemini Clinical Trial Site 15, Charlotte
Gemini Clinical Trial Site 2, Asheville
Gemini Clinical Trial Site 13, Beaufort
Gemini Clinical Trial Site 5, Miami
Gemini Clinical Trial Site 7, Pinellas Park
Gemini Clinical Trial Site 18, Winter Haven
Gemini Clinical Trial Site 20, Sarasota
Gemini Clinical Trial Site 8, Stuart
Gemini Clinical Trial Site 6, Cincinnati
Gemini Clinical Trial Site 19, Indianapolis
Gemini Clinical Trial Site 22, Royal Oak
Gemini Clinical Trial Site 3, Dallas
Gemini Clinical Trial Site 21, San Antonio
Gemini Clinical Trial Site 14, San Antonio
Gemini Clinical Trial Site 16, Phoenix
Gemini Clinical Trial Site 1, Reno
Gemini Clinical Trial Site 12, Pasadena
Gemini Clinical Trial Site 9, Encino
Gemini Clinical Trial Site 17, Huntington Beach
Gemini Clinical Trial Site 11, Campbell
Gemini Clinical Trial Site 10, Eugene
Gemini Clinical Trial Site 23, Worcester
Lead Sponsor
Gemini Therapeutics, Inc.
INDUSTRY